SLT (Selective Laser Trabeculoplasty) is a highly effective laser therapy for the treatment of glaucoma. This repeatable, non-invasive treatment stimulates a process of cellular regeneration to reduce the elevated intraocular pressure (IOP) associated with glaucoma, without the burn and scar tissue associated with other laser procedures.
SLT is a highly effective approach for first-line glaucoma therapy. It is also effective as adjunct therapy with drugs, and as alternative therapy when drugs or surgery fail. Most importantly, SLT enables you to control your patients’ glaucoma treatment without the compliance issues and side effects associated with drug therapy.
SLT was developed specifically as a treatment for the reduction of IOP in patients suffering from primary open-angle glaucoma (POAG) by Mark Latina, MD, Associate Clinical Professor of Ophthalmology at Tufts University in Boston, in collaboration with Massachusetts General Hospital. It was cleared by the U.S. Food and Drug Administration (FDA) in March 2001.
When compared to ALT, SLT uses 6000 times less energy density (fluence) to activate the desired biologic response. This response takes place at a cellular level, producing a wound-healing effect in the eye, without causing structural damage to the trabecular meshwork.